- Home
- SOAR vs AIMD Comparison
SOAR vs AIMD Comparison
Compare SOAR & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOAR
- AIMD
- Stock Information
- Founded
- SOAR 2021
- AIMD 1984
- Country
- SOAR United States
- AIMD United States
- Employees
- SOAR N/A
- AIMD N/A
- Industry
- SOAR Blank Checks
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- SOAR Finance
- AIMD Health Care
- Exchange
- SOAR Nasdaq
- AIMD Nasdaq
- Market Cap
- SOAR 7.1M
- AIMD 6.0M
- IPO Year
- SOAR N/A
- AIMD N/A
- Fundamental
- Price
- SOAR $0.26
- AIMD $0.46
- Analyst Decision
- SOAR
- AIMD
- Analyst Count
- SOAR 0
- AIMD 0
- Target Price
- SOAR N/A
- AIMD N/A
- AVG Volume (30 Days)
- SOAR 18.1M
- AIMD 132.1K
- Earning Date
- SOAR 11-18-2024
- AIMD 11-06-2024
- Dividend Yield
- SOAR N/A
- AIMD N/A
- EPS Growth
- SOAR N/A
- AIMD N/A
- EPS
- SOAR N/A
- AIMD N/A
- Revenue
- SOAR $102,271,000.00
- AIMD $40,633.00
- Revenue This Year
- SOAR N/A
- AIMD N/A
- Revenue Next Year
- SOAR N/A
- AIMD N/A
- P/E Ratio
- SOAR N/A
- AIMD N/A
- Revenue Growth
- SOAR 97.25
- AIMD N/A
- 52 Week Low
- SOAR $0.17
- AIMD $0.40
- 52 Week High
- SOAR $4.50
- AIMD $4.29
- Technical
- Relative Strength Index (RSI)
- SOAR 45.52
- AIMD 49.75
- Support Level
- SOAR $0.23
- AIMD $0.42
- Resistance Level
- SOAR $0.32
- AIMD $0.48
- Average True Range (ATR)
- SOAR 0.04
- AIMD 0.04
- MACD
- SOAR -0.00
- AIMD 0.00
- Stochastic Oscillator
- SOAR 7.36
- AIMD 36.48
About SOAR Volato Group Inc.
Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.